GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

Student Workbook This student workbook was prepared for the Agency for Healthcare Research and Quality by RAND Corporation under contract 290-06-00017-7. It is one component of a four-part set of ...

Timely PPCI confers improved survival compared with fibrinolytic therapy as primary reperfusion therapy for patients with STEMI. 6,7 Systems of care designed to reduce the time to PPCI for patients ...